Anti-PBM Value Rescription positions itself as an anti-PBM with a subscription model and pass-through pricing, offering substantial drug savings and a transparent approach. Sales can target employers and health systems seeking core cost reductions without rebate games.

Strategic Partnerships Recent collaboration with New Bridge Medical Center indicates a pathway for expanding employer prescription programs in New Jersey. Target hospitals, integrated delivery networks, and employer groups in regions with 340B capabilities and international sourcing potential.

Industry Differentiator The combination of 340B purchasing, international sourcing, and a proprietary AI-enabled platform creates a unique value proposition for large purchasers seeking predictable pricing and broad drug choices without incentive misalignment.

Tech Enabled Utilization of scalable tech stack including AWS, SSO-enabled collaboration tools, and AI-driven workflow supports efficient onboarding and transparent savings calculations, which can be attractive for health systems prioritizing digital procurement solutions.

Growth Signals Mid-market focus with 10-25 million in annual revenue and a lean team suggests scalability opportunities through employer-based prescription programs, regional hospital networks, and PBM-adjacent partnerships that require cost containment and simple implementation.